[{"edinetCode":"E00920","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":17202.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":634446000.0,"sharesOwendPercent":0.2945,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":14.1,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2017\/6\/19","stockCode":4503,"accountingYear":"第12期（自　2016年４月１日　至　2017年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":16617.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":627377000.0,"sharesOwendPercent":0.3173,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":19.9,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2018\/6\/15","stockCode":4503,"accountingYear":"第13期（自　2017年４月１日　至　2018年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":16243.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":618842000.0,"sharesOwendPercent":0.3279,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1897650000000.0,"currentAssets":857159000000.0,"fixedAsset":null,"tangibleFixedAssets":173483000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":639252000000.0,"currentLiabilities":497665000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177301000000.0,"accumulatedEarnings":991957000000.0,"treasuryStock":-164629000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":292050000000.0,"grossProfit":null,"sgaExpenses":490263000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":14.4,"roe":null,"cashFlowFromOperatingActivities":258630000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-41757000000.0,"cashFlowFromFinancialActivities":-233681000000.0,"changesInCashAndCashEquivalents":-20657000000.0,"列1":"asr","submitDate":"2019\/6\/18","stockCode":4503,"accountingYear":"第14期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1927030000000.0,"currentAssets":820130000000.0,"fixedAsset":null,"tangibleFixedAssets":251898000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":677323000000.0,"currentLiabilities":464162000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177087000000.0,"accumulatedEarnings":854412000000.0,"treasuryStock":-4613000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":70512000000.0,"grossProfit":null,"sgaExpenses":117470000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":7412000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-13985000000.0,"cashFlowFromFinancialActivities":-40354000000.0,"changesInCashAndCashEquivalents":-51652000000.0,"列1":"q1r","submitDate":"2019\/8\/6","stockCode":4503,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":635600000.0,"sharesOwendPercent":0.3367,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1979820000000.0,"currentAssets":855596000000.0,"fixedAsset":null,"tangibleFixedAssets":254707000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":683681000000.0,"currentLiabilities":483626000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177163000000.0,"accumulatedEarnings":924739000000.0,"treasuryStock":-5554000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":138872000000.0,"grossProfit":null,"sgaExpenses":226067000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":101659000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-46553000000.0,"cashFlowFromFinancialActivities":-45956000000.0,"changesInCashAndCashEquivalents":293000000.0,"列1":"q2r","submitDate":"2019\/11\/12","stockCode":4503,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":277602000000.0,"assets":1989780000000.0,"currentAssets":834150000000.0,"fixedAsset":null,"tangibleFixedAssets":260902000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":672333000000.0,"currentLiabilities":466058000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177256000000.0,"accumulatedEarnings":949853000000.0,"treasuryStock":-42410000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":221642000000.0,"grossProfit":null,"sgaExpenses":353575000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":170290000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-74386000000.0,"cashFlowFromFinancialActivities":-125232000000.0,"changesInCashAndCashEquivalents":-33472000000.0,"列1":"q3r","submitDate":"2020\/2\/7","stockCode":4503,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":15883.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":667359000.0,"sharesOwendPercent":0.3587,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2318160000000.0,"currentAssets":867514000000.0,"fixedAsset":null,"tangibleFixedAssets":268600000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":1028990000000.0,"currentLiabilities":798708000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177506000000.0,"accumulatedEarnings":905851000000.0,"treasuryStock":-7178000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":276739000000.0,"grossProfit":null,"sgaExpenses":499295000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":16.0,"roe":null,"cashFlowFromOperatingActivities":221998000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-389793000000.0,"cashFlowFromFinancialActivities":181055000000.0,"changesInCashAndCashEquivalents":7317000000.0,"列1":"asr","submitDate":"2020\/6\/18","stockCode":4503,"accountingYear":"第15期 (自　2019年４月１日　至　2020年３月31日) ","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":239934000000.0,"assets":2256040000000.0,"currentAssets":795979000000.0,"fixedAsset":null,"tangibleFixedAssets":267107000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":949351000000.0,"currentLiabilities":647672000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177183000000.0,"accumulatedEarnings":918890000000.0,"treasuryStock":-7423000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":59654000000.0,"grossProfit":null,"sgaExpenses":120776000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":21600000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-28330000000.0,"cashFlowFromFinancialActivities":-72977000000.0,"changesInCashAndCashEquivalents":-78457000000.0,"列1":"q1r","submitDate":"2020\/8\/7","stockCode":4503,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":677903000.0,"sharesOwendPercent":0.3643,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":286734000000.0,"assets":2237020000000.0,"currentAssets":819902000000.0,"fixedAsset":null,"tangibleFixedAssets":265670000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":907389000000.0,"currentLiabilities":616933000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177452000000.0,"accumulatedEarnings":941847000000.0,"treasuryStock":-7311000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":119549000000.0,"grossProfit":null,"sgaExpenses":242135000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":114960000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-38285000000.0,"cashFlowFromFinancialActivities":-109736000000.0,"changesInCashAndCashEquivalents":-31657000000.0,"列1":"q2r","submitDate":"2020\/11\/6","stockCode":4503,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":306514000000.0,"assets":2296840000000.0,"currentAssets":863294000000.0,"fixedAsset":null,"tangibleFixedAssets":255178000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":928235000000.0,"currentLiabilities":635847000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177644000000.0,"accumulatedEarnings":963012000000.0,"treasuryStock":-7184000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":187736000000.0,"grossProfit":null,"sgaExpenses":363044000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":225143000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-67735000000.0,"cashFlowFromFinancialActivities":-171337000000.0,"changesInCashAndCashEquivalents":-11877000000.0,"列1":"q3r","submitDate":"2021\/2\/5","stockCode":4503,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":15455.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":686078000.0,"sharesOwendPercent":0.3687,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2273630000000.0,"currentAssets":872588000000.0,"fixedAsset":null,"tangibleFixedAssets":264623000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":887513000000.0,"currentLiabilities":592372000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177830000000.0,"accumulatedEarnings":953289000000.0,"treasuryStock":-15377000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":246063000000.0,"grossProfit":null,"sgaExpenses":504316000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":26.2,"roe":null,"cashFlowFromOperatingActivities":306843000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-81894000000.0,"cashFlowFromFinancialActivities":-229479000000.0,"changesInCashAndCashEquivalents":7737000000.0,"列1":"asr","submitDate":"2021\/6\/18","stockCode":4503,"accountingYear":"第16期 (自　2020年４月１日　至　2021年３月31日) ","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":301920000000.0,"assets":2249460000000.0,"currentAssets":868715000000.0,"fixedAsset":null,"tangibleFixedAssets":269698000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":866587000000.0,"currentLiabilities":581580000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":177657000000.0,"accumulatedEarnings":945961000000.0,"treasuryStock":-15663000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":62231000000.0,"grossProfit":null,"sgaExpenses":137109000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":40083000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-21085000000.0,"cashFlowFromFinancialActivities":-44730000000.0,"changesInCashAndCashEquivalents":-24208000000.0,"列1":"q1r","submitDate":"2021\/8\/6","stockCode":4503,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":756327000.0,"sharesOwendPercent":0.4064,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":318295000000.0,"assets":2261510000000.0,"currentAssets":876454000000.0,"fixedAsset":null,"tangibleFixedAssets":266671000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":843886000000.0,"currentLiabilities":554768000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":178531000000.0,"accumulatedEarnings":985231000000.0,"treasuryStock":-15605000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":124736000000.0,"grossProfit":null,"sgaExpenses":270506000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":139385000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-55744000000.0,"cashFlowFromFinancialActivities":-89936000000.0,"changesInCashAndCashEquivalents":-7834000000.0,"列1":"q2r","submitDate":"2021\/11\/5","stockCode":4503,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00920","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":350213000000.0,"assets":2356250000000.0,"currentAssets":939331000000.0,"fixedAsset":null,"tangibleFixedAssets":267817000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":889954000000.0,"currentLiabilities":597976000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":103001000000.0,"capitalSurplus":179042000000.0,"accumulatedEarnings":999640000000.0,"treasuryStock":-15520000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":194094000000.0,"grossProfit":null,"sgaExpenses":406420000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":208859000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-47586000000.0,"cashFlowFromFinancialActivities":-141264000000.0,"changesInCashAndCashEquivalents":24085000000.0,"列1":"q3r","submitDate":"2022\/2\/7","stockCode":4503,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00920","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":103000,"settlementDate":"2022\/3\/31","submitterName":"アステラス製薬株式会社","submitterNameEnglish":"Astellas Pharma Inc.","submitterNameKana":"アステラスセイヤクカブシキガイシャ","location":"中央区日本橋本町二丁目５番１号","industory":"医薬品","corporateNumber":5010000000000.0}]